Trial Profile
A safety and efficacy study of Nivolumab in patients with non-microcytic pulmonary cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2018
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 03 Apr 2018 New trial record